First Interstate Bank Buys 23,154 Shares of Pfizer Inc. $PFE

First Interstate Bank boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,491 shares of the biopharmaceutical company’s stock after purchasing an additional 23,154 shares during the quarter. First Interstate Bank’s holdings in Pfizer were worth $4,217,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Norges Bank bought a new stake in shares of Pfizer in the 2nd quarter valued at about $2,270,157,000. Vanguard Group Inc. grew its holdings in Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after purchasing an additional 10,198,330 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after purchasing an additional 5,662,309 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of Pfizer by 75.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after purchasing an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after purchasing an additional 3,472,240 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. UBS Group started coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Finally, HSBC reiterated a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $27.88.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: License deal for Matrix‑M adjuvant could accelerate Pfizer’s vaccine programs and support pipeline expansion; this is a concrete R&D/capability win. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Recent quarterly results and FY‑2025 guidance (EPS range ~3.00–3.15) show profit generation and set expectations for the year, supporting baseline valuation (beat on EPS, mixed on revenue).
• Neutral Sentiment: JPMorgan conference takeaways highlight industry-wide themes — drug pricing pressure, looming patent cliffs, and dealmaking — that shape mid‑cycle expectations for big pharma including Pfizer. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Neutral Sentiment: Analyst pieces compare Pfizer to peers (e.g., Eli Lilly) on growth outlook and product mix; these comparisons keep PFE under scrutiny but don’t change fundamentals immediately. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Neutral Sentiment: Quarterly outlook notes (non‑oncology) — Eliquis strength vs softer COVID sales — imply mixed revenue drivers heading into the next report. What to Expect From Pfizer’s Non-Oncology Business in Q4?
• Neutral Sentiment: Thematic ETF/sector coverage pieces mention PFE exposure among obesity/GLP-1 and vaccine plays, which can attract longer‑term interest but provide limited near‑term price support. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (PFE)
• Negative Sentiment: CEO Albert Bourla said U.S. drug prices are coming down — investors interpret this as potential margin and top‑line pressure from pricing reform and negotiations. Pfizer CEO Albert Bourla: U.S. drug prices are coming down
• Negative Sentiment: Pfizer is exiting parts of the ViiV HIV joint venture as partners reshuffle stakes, reducing exposure to the JV’s future upside and simplifying the company footprint. Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
• Negative Sentiment: Longer‑term skepticism persists (coverage pieces noting the stock is down materially from peak due to past trial failures and upcoming patent cliffs), which keeps valuation under pressure and can limit rebounds. Down 55%, Should You Buy the Dip on Pfizer?

Pfizer Stock Performance

PFE opened at $25.52 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The firm has a 50 day moving average of $25.38 and a two-hundred day moving average of $24.99. The firm has a market capitalization of $145.07 billion, a PE ratio of 14.83 and a beta of 0.47.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.